Complex | |
AACDB_ID: | 7210 |
PDBID: | 7MEJ |
Chains: | B_R |
Organism: | Lama glama, Severe acute respiratory syndrome coronavirus 2 |
Method: | EM |
Resolution (Å): | 3.55 |
Reference: | 10.1038/s41467-021-24963-3 |
Antibody | |
Antibody: | 36 Nanobody |
Antibody mutation: | No |
INN (Clinical Trial): | |
Antigen | |
Antigen: | SARS-CoV-2 spike glycoprotein RBD |
Antigen mutation: | No |
Durg Target: | P0DTC2; P0DTC2; |
Antibody
Chain: B
Mutation: NULL
>7MEJ_B|Chain C[auth B]|Nanobody Nb36|Lama glama (9844) VQLVESGGGLVQAGGSLTLTCAASGRTFSSETMDMGWFRQAPGKEREFVAADSWNDGSTYYADSVKGRFTISRDSAKNTLYLQMNSLKPEDTAVYYCAAETYSIYEKDDSWGYWGQGTQVTVS |
Antigen
Chain: R
Mutation: NULL
>7MEJ_R|Chain B[auth R]|Spike protein S1|Severe acute respiratory syndrome coronavirus 2 (2697049) TNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCG |
Interaction
1、Solvent accessible surface areas (SASA) were calculated (Naccess V2.1.1) for each residue in antibody and antigen, respectively. The residues with SASA loss in binding of more than 1Å2 were classified as interacting residues.
Interacting residues (ΔSASA based)
B: ARG27 PHE37 TYR97 SER98 ILE99 TRP100 GLY101 TYR102 GLN105 R: ARG346 PHE347 ALA348 SER349 TYR351 ALA352 TRP353 ASN354 ARG355 LYS356 ARG357 PHE464 GLU465 ARG466 ASP467 ILE468 THR470 |
2、We defined interacting paratope-epitope residues by a distance cutoff of < 5Å . Two amino acids are considered as interacting residues if they have at least one atom within a distance of 5 Å from any atom.
Interacting residues (Atom distance based)